AstraZeneca PLC (AZN)
| Market Cap | 240.55B -8.2% |
| Revenue (ttm) | 61.37B +8.6% |
| Net Income | 10.45B +25.9% |
| EPS | 6.68 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 23.40 |
| Forward PE | 14.61 |
| Dividend | $3.23 (2.07%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 2,910,481 |
| Open | 160.76 |
| Previous Close | 158.33 |
| Day's Range | 154.00 - 160.83 |
| 52-Week Range | 153.41 - 212.71 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 207.16 (+32.95%) |
| Earnings Date | Oct 30, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is $207.16, which is an increase of 32.95% from the latest price.
News
AstraZeneca upgraded to Buy from Sell at Nordea
Nordea double upgraded AstraZeneca (AZN) to Buy from Sell with a price target of SEK 1,900, up from SEK 1,650. The firm sees investor focus returning to the company’s heart…
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint
Astrazeneca NYSE: AZN presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at the American Society for Bone and Mineral Research ann...
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAstrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for h...
AstraZeneca Transcript: AZN Meet The Management at ASBMR 2026
Efzimfotase alfa missed HICKORY’s week-25 Six-Minute Walk Test primary endpoint, but showed benefits across pain, fatigue and function, with continued gains in the extension. Peak sales guidance remains $3B–$5B; FDA priority review covers the full dataset.
AstraZeneca Slides: FY 2026
AstraZeneca has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 12, 2026.
AstraZeneca Young Health Programme and UNICEF partner to advance health equity in Thailand
AstraZeneca has announced a total investment of more than US$100 million in its Young Health Programme (YHP) between 2010 and 2030, supporting its commitment to advancing health equity in more than 60...
Efzimfotase Alfa Shows Encouraging Trend in HPP Trial; AstraZeneca (AZN) Dividend Remains Attractive
Efzimfotase Alfa Shows Encouraging Trend in HPP Trial; AstraZeneca (AZN) Dividend Remains Attractive
AstraZeneca announces ALXN1850 did not achieve statistical significance
Results from the HICKORY Phase III trial showed that efzimfotase alfa, ALXN1850, did not achieve statistical significance but demonstrated a numerical improvement in the primary endpoint of Six-Minute...
Guardant Health Announces Approval in Europe of Guardant360 CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in Advanced ER-positive Breast Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360 CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as ...
Myriad Genetics (MYGN) Partners with AstraZeneca and SOPHiA Genetics to Advance Prostate Cancer ...
Myriad Genetics (MYGN) Partners with AstraZeneca and SOPHiA Genetics to Advance Prostate Cancer Genomic Testing
SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology
(RTTNews) - SOPHiA GENETICS (SOPH) and Myriad Genetics, Inc. (MYGN) announced Thursday a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support p...
Myriad, Sophia advance prostate cancer-specific genomic instability score tech
Myriad Genetics (MYGN) and Sophia Genetics (SOPH) announced a collaboration to advance new prostate cancer-specific genomic instability score technology to support precision oncology approaches with A...
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) t...
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability...
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Astrazeneca (AZN) closed at $158.61, marking a +1.33% move from the previous day.
AstraZeneca price target raised to 18,600 GBp from 17,800 GBp at Citi
Citi raised the firm’s price target on AstraZeneca (AZN) to 18,600 GBp from 17,800 GBp and keeps a Buy rating on the shares.
AstraZeneca Opens New $1 Bln R&D Hub To Strengthen Global Drug Research
(RTTNews) - Global biopharmaceutical company, AstraZeneca PLC (AZN) announced that it has opened a new strategic research and development (R&D) centre in Kendall Square, Cambridge, Massachusetts.
AstraZeneca CEO Optimistic on Growth Beyond 2030 Without Major Acquisitions (NYSE: AZN)
AstraZeneca CEO Optimistic on Growth Beyond 2030 Without Major Acquisitions (NYSE: AZN)
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics' lead drug could help power next-generation cancer combinations that could be the "future of cancer care." Soriot spoke exclusively wit...
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot
CNBC’s Annika Kim Constantino and Pascal Soriot, AstraZeneca CEO, join 'The Exchange' to discuss its $50 billion investment in stateside manufacturing and opening an research and development site in B...
AstraZeneca CEO Pascal Soriot on new Boston site: Faster, better development of new products is the hope
CNBC’s Annika Kim Constantino and Pascal Soriot, AstraZeneca CEO, join 'The Exchange' to discuss its $50 billion investment in stateside manufacturing and opening an research and development site in B...
AstraZeneca Opens New R&D Center in Cambridge, Boosting Innovation Pipeline (AZN)
AstraZeneca Opens New R&D Center in Cambridge, Boosting Innovation Pipeline (AZN)
AstraZeneca to invest over $1 billion in Massachusetts, boost workforce
AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 billion US investment plan, a move expected to expand its workforce in the state by more th...
AstraZeneca opens R&D center in Cambridge, Massachusetts
AstraZeneca (AZN) today announced the opening of its newest global strategic research and development center, in Kendall Square, Cambridge, Massachusetts. The new state-of-the-art facility builds on t...
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the opening of its newest global strategic research and development (R&D) center, in Kendall Square, Cambridge, Massachusetts. The new st...